Spevigo® (spesolimab-sbzo)
for Psoriasis

Spevigo (spesolimab-sbzo) is an interleukin inhibitor used to treat generalized pustular psoriasis (GPP) in adults and children aged 12 and older, weighing at least 88 pounds (40 kg). It is given as an intravenous infusion for GPP flares and as a subcutaneous injection every 4 weeks for maintenance. Spevigo works by blocking the interleukin-36 receptor (IL-36R), which plays a key role in inflammation and immune responses associated with GPP. The exact mechanism of action is not fully understood.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Psoriasis